Usana Health Sciences Lowers FY22 Outlook

Usana Health Sciences Inc. (USNA) Wednesday lowered its outlook for the full year 2022.

Looking forward to the full year 2022, the company now expects earnings of $3.85 to $4.45 per share and revenues of $1.015 billion to $1.065 billion. Previously, the company expected earnings of $5.00 to $5.70 per share and revenues of $1.100 billion to $1.200 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $5.27 per share and revenues of $1.13 billion.

"Our sales performance during the second quarter was below expectations, as COVID-related lockdowns, restrictions, and other disruptions continued in mainland China and other markets," said Kevin Guest, Chief Executive Officer and Chairman of the Board. "These challenges were particularly disruptive to the regional sales program we offered in several key markets during the quarter, and ultimately caused participation in the program, sales results and active customer counts to come in lower than anticipated.

The company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be about $1.05, which compares with $1.87 during the second quarter of 2021. Analysts currently estimate earnings of $1.26 per share and revenues of $272.77 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT